Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | |
---|---|---|---|---|---|
Total Debt to Total Equity | 3.0x | (1.6x) | (1.0x) | 6.8x | 0.1x |
Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | |
---|---|---|---|---|---|
% growth | 0.1 0.0% | 0.0 (60.1%) | 0.0 (43.9%) | 0.0 (64.2%) | 0.0 261.2% |
Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
% margin | 0.0 27.6% | 0.0 58.3% | 0.0 45.1% | 0.0 45.7% | 0.0 67.3% |
Operating Expenses | 3.8 | 2.6 | 4.7 | 6.1 | 6.3 |
Research & Development Expenses (R&D) | 2.0 | 1.7 | 3.0 | 2.5 | 2.9 |
Selling, General & Administrative Expenses (SG&A) | 1.8 | 0.9 | 1.7 | 3.7 | 3.4 |
% margin | (3.8) (5,949.0%) | (2.6) (10,030.2%) | (4.7) (32,765.6%) | (6.1) (118,698.3%) | (6.3) (33,902.0%) |
Interest Income | 0.0 | 0.1 | 0.4 | 0.2 | 0.0 |
Interest Expense | 0.0 | 0.1 | 0.4 | 0.2 | 0.4 |
Pre-tax Income | (3.8) | (2.5) | (4.8) | (6.4) | (6.6) |
% effective tax rate | 0.0 (0.6%) | 0.1 (5.3%) | (0.3) 5.2% | 484.5 (7,624.8%) | 0.0 0.0% |
% margin | (3.8) (5,973.4%) | (2.6) (10,081.1%) | (4.6) (31,851.8%) | (490.9) (9,531,151.3%) | (6.6) (35,511.9%) |
EPS | (115.69) | (77.89) | (137.94) | (6,173.88) | (18.74) |
Diluted EPS | (115.69) | (77.89) | (137.94) | (6,173.88) | (18.74) |
% margin | (3.7) (5,834.2%) | (2.3) (8,928.7%) | (4.4) (30,822.2%) | (6.1) (118,139.8%) | (6.2) (33,096.7%) |
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
As of today, Microsoft Corp's last 12-month Total Debt to Total Equity is 722.9x, based on the financial report for Oct 31, 2024 (Q4’2024). The average annual Total Debt to Total Equity for Heart Test Laboratories, Inc. have been 47.8x over the past three years, and 35.9x over the past five years.
As of today, Heart Test Laboratories, Inc.'s Total Debt to Total Equity is 722.9x, which is higher than industry median of 0.1x. It indicates that Heart Test Laboratories, Inc.'s Total Debt to Total Equity is Bad.